LOG IN
SIGN UP
MARKET
ACXP
ACXP
Acurx Pharmaceuticals Inc
NASDAQ
Real-time Quotes | Nasdaq Last Sale
3.790
+0.160
+4.41%
Closed 18:06 06/30 EDT
OPEN
3.690
PREV CLOSE
3.630
HIGH
3.830
LOW
3.520
VOLUME
27.72K
TURNOVER
--
52 WEEK HIGH
6.84
52 WEEK LOW
2.330
MARKET CAP
38.90M
P/E (TTM)
-2.4411
1D
5D
1M
3M
1Y
5Y
91 Biggest Movers From Friday
Gainers RISE Education Cayman Ltd (NYSE: REDU) shares jumped 138.5% to settle at $3.41 on Friday. RISE Education announced expected timing for the completion of the merger with Dada Auto.
Benzinga · 06/13 08:28
Acurx Pharmaceuticals GAAP EPS of -$0.26 beats by $0.07
Acurx Pharmaceuticals press release (NASDAQ:ACXP): Q1 GAAP EPS of -$0.26 beats by $0.07. Cash balance of $1.08M as of March31, 2022
Seekingalpha · 05/11 11:15
-- Earnings Flash (ACXP) ACURX PHARMACEUTICALS Posts Q1 Loss $-0.26
MT Newswires · 05/11 07:15
Acurx Pharmaceuticals, Inc. to Discuss 2022 First Quarter Financial Results on May 11, 2022 Conference Call and Provide Business Update
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will release its 2022 firs...
PR Newswire · 04/29 12:01
Acurx Pharmaceuticals (NASDAQ:ACXP) Is In A Good Position To Deliver On Growth Plans
We can readily understand why investors are attracted to unprofitable companies. For example, although...
Simply Wall St. · 03/24 19:23
Acurx Pharmaceuticals GAAP EPS of -$1.49 beats by $0.20
Acurx Pharmaceuticals press release (NASDAQ:ACXP): FY GAAP EPS of -$1.49 beats by $0.20. Cash balance of $12.96M as of December 31, 2021
Seekingalpha · 03/17 11:30
BRIEF-Acurx Pharmaceuticals Reports Q4, Full Year 2021 Results And Provides Business Update
reuters.com · 03/17 11:08
Acurx Pharmaceuticals to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28-30, 2022 from 9:00 a.m. - 5:00 p.m. EDT
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that Company's President & CEO, David P. Lu...
PR Newswire · 03/16 12:01
No Data
Learn about the latest financial forecast of ACXP. Analyze the recent business situations of Acurx Pharmaceuticals Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating
Based on 1 analysts
Buy
Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.
0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ACXP stock price target is 12.00 with a high estimate of 12.00 and a low estimate of 12.00.
Current 3.790
EPS
Actual
Estimate
-0.46-0.34-0.23-0.11
Institutional Holdings
Institutions: 8
Institutional Holdings: 318.11K
% Owned: 3.10%
Shares Outstanding: 10.26M
TypeInstitutionsShares
Increased
2
12.76K
New
3
280.29K
Decreased
1
15.00K
Sold Out
5
33.42K
- Performance
- Asset Allocation
- Dividend History
No Data
No Data
No Data
No Data
About ACXP
Acurx Pharmaceuticals, Inc., formerly Acurx Pharmaceuticals, LLC, is a clinical-stage biopharmaceutical company. The Company is engaged in developing a class of antibiotics for infections caused by bacteria listed as pathogens by the World Health Organization (WHO), the United States Centers for Disease Control and Prevention, and the United States Food and Drug Administration (FDA). The Company develops antibiotic candidates that block the deoxyribonucleic acid (DNA) polymerase IIIC enzyme (Pol IIIC). Pol IIIC is the primary catalyst for DNA replication in Gram-positive bacterial cells. Its research and development pipeline include clinical-stage and early-stage antibiotic candidates that target Gram-positive bacteria for oral and/or parenteral treatment of infections caused by Clostridium difficile, Enterococcus, including vancomycin-resistant strains (VRE), Staphylococcus, including methicillin-resistant strains (MRSA) and Streptococcus, including antibiotic resistant strains.
Webull offers kinds of Acurx Pharmaceuticals Inc stock information, including NASDAQ:ACXP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACXP stock news, and many more online research tools to help you make informed decisions.
You can practice and explore trading ACXP stock methods without spending real money on the virtual paper trading platform.